Penumbra, Inc.
PEN
Rangering i aksjer
#1678
Penumbra, Inc., together with its subsidiaries, designs, develops,... Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Aksjekurs
$324.23
Markedsverdi
$12.77B
Endring (1 dag)
0.45%
Endring (1 år)
30.94%
Land
US
Handel Penumbra, Inc. (PEN)
Kategori
Healthcare
P/E-forhold for Penumbra, Inc. (PEN)
P/E-forhold per October 2026 TTM: 78.27
Ifølge Penumbra, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 78.27. Ved slutten av 2023 hadde selskapet en P/E på 106.20.
P/E-forholdshistorikk for Penumbra, Inc. fra 2012 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 78.27 | -88.05% |
| 2024 | 654.78 | 516.55% |
| 2023 | 106.20 | -102.53% |
| 2022 | -4.20K | -310.34% |
| 2021 | 2.00K | -601.49% |
| 2020 | -398.62 | -438.38% |
| 2019 | 117.80 | -82.37% |
| 2018 | 668.05 | 0.25% |
| 2017 | 666.36 | 407.88% |
| 2016 | 131.20 | -51.92% |
| 2015 | 272.88 | -39.48% |
| 2014 | 450.91 | 82.58% |
| 2013 | 246.96 | -52.23% |
| 2012 | 517.00 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 33.11 | -57.70% |
US
|
|
| 21.39 | -72.67% |
IE
|
|
| 28.94 | -63.02% |
US
|
|
| 17.34 | -77.85% |
US
|
|
| - | - |
DE
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.